{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:56:29Z","timestamp":1783166189430,"version":"3.54.6"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Failure Clinics"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.hfc.2024.02.002","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:28:02Z","timestamp":1712575682000},"page":"261-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pathophysiology of Cardiac Amyloidosis"],"prefix":"10.1016","volume":"20","author":[{"given":"Paolo","family":"Morfino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Franzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"issue":"10038","key":"10.1016\/j.hfc.2024.02.002_bib2","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hfc.2024.02.002_bib3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","article-title":"Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade","volume":"86","author":"Chiti","year":"2017","journal-title":"Annu Rev Biochem"},{"issue":"12","key":"10.1016\/j.hfc.2024.02.002_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123054","article-title":"Tissue characterization in cardiac amyloidosis","volume":"10","author":"Musetti","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.hfc.2024.02.002_bib5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11897-016-0311-y","article-title":"New and evolving concepts regarding the prognosis and treatment of cardiac amyloidosis","volume":"13","author":"Perlini","year":"2016","journal-title":"Curr Heart Fail Rep"},{"issue":"24","key":"10.1016\/j.hfc.2024.02.002_bib6","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.hfc.2024.02.002_bib7","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.hfc.2024.02.002_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCIMAGING.123.015259","article-title":"Rare forms of cardiac amyloidosis: diagnostic clues and phenotype in Apo AI and AIV Amyloidosis","volume":"16","author":"Ioannou","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.hfc.2024.02.002_bib9","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"issue":"6","key":"10.1016\/j.hfc.2024.02.002_bib10","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.hfc.2024.02.002_bib11","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.biochi.2012.07.011","article-title":"What does make an amyloid toxic: morphology, structure or interaction with membrane?","volume":"95","author":"Berthelot","year":"2013","journal-title":"Biochimie"},{"key":"10.1016\/j.hfc.2024.02.002_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","article-title":"The genetics of the amyloidoses","volume":"51","author":"Buxbaum","year":"2000","journal-title":"Annu Rev Med"},{"issue":"12","key":"10.1016\/j.hfc.2024.02.002_bib14","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1073\/pnas.91.12.5446","article-title":"A\u00a0role for destabilizing amino acid replacements in light-chain amyloidosis","volume":"91","author":"Hurle","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.hfc.2024.02.002_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1006\/clin.1994.1070","article-title":"Preferential expression of human lambda-light-chain variable-region subgroups in multiple myeloma, AL amyloidosis, and Waldenstr\u00f6m's macroglobulinemia","volume":"71","author":"Ozaki","year":"1994","journal-title":"Clin Immunol Immunopathol"},{"issue":"9","key":"10.1016\/j.hfc.2024.02.002_bib16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0968-0004(99)01445-0","article-title":"Protein misfolding, evolution and disease","volume":"24","author":"Dobson","year":"1999","journal-title":"Trends Biochem Sci"},{"issue":"12","key":"10.1016\/j.hfc.2024.02.002_bib17","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41580-018-0060-8","article-title":"A\u00a0new era for understanding amyloid structures and disease","volume":"19","author":"Iadanza","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"10.1016\/j.hfc.2024.02.002_bib18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"28","key":"10.1016\/j.hfc.2024.02.002_bib20","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"6968","key":"10.1016\/j.hfc.2024.02.002_bib21","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/nature02261","article-title":"Protein folding and misfolding","volume":"426","author":"Dobson","year":"2003","journal-title":"Nature"},{"issue":"5446","key":"10.1016\/j.hfc.2024.02.002_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1126\/science.286.5446.1888","article-title":"Posttranslational quality control: folding, refolding, and degrading proteins","volume":"286","author":"Wickner","year":"1999","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.hfc.2024.02.002_bib23","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1110\/ps.03234503","article-title":"Beta edge strands in protein structure prediction and aggregation","volume":"12","author":"Siepen","year":"2003","journal-title":"Protein Sci"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib24","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/13506129.2016.1257986","article-title":"Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines","volume":"23","author":"Sipe","year":"2016","journal-title":"Amyloid"},{"key":"10.1016\/j.hfc.2024.02.002_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-1-61779-551-0_9","article-title":"X-ray fibre diffraction studies of amyloid fibrils","volume":"849","author":"Morris","year":"2012","journal-title":"Methods Mol Biol"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib26","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1038\/s41467-020-17207-3","article-title":"Structure-based machine-guided mapping of amyloid sequence space reveals uncharted sequence clusters with higher solubilities","volume":"11","author":"Louros","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.hfc.2024.02.002_bib27","doi-asserted-by":"crossref","first-page":"102343","DOI":"10.1016\/j.sbi.2022.102343","article-title":"Computational methods to predict protein aggregation","volume":"73","author":"Navarro","year":"2022","journal-title":"Curr Opin Struct Biol"},{"issue":"31","key":"10.1016\/j.hfc.2024.02.002_bib28","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1021\/bi050724t","article-title":"Parallel beta-sheets and polar zippers in amyloid fibrils formed by residues 10-39 of the yeast prion protein Ure2p","volume":"44","author":"Chan","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.hfc.2024.02.002_bib29","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1039\/C1SM06643A","article-title":"Inhibiting, promoting, and preserving stability of functional protein fibrils","volume":"8","author":"Jones","year":"2012","journal-title":"Soft Matter"},{"issue":"5","key":"10.1016\/j.hfc.2024.02.002_bib30","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1073\/pnas.052706099","article-title":"Natural beta-sheet proteins use negative design to avoid edge-to-edge aggregation","volume":"99","author":"Richardson","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.hfc.2024.02.002_bib31","doi-asserted-by":"crossref","first-page":"e89781","DOI":"10.1371\/journal.pone.0089781","article-title":"Sequence complexity of amyloidogenic regions in intrinsically disordered human proteins","volume":"9","author":"Das","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.hfc.2024.02.002_bib32","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.hfc.2024.02.002_bib33","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jmb.2008.07.029","article-title":"Structural insight into pH-induced conformational changes within the native human transthyretin tetramer","volume":"382","author":"Palaninathan","year":"2008","journal-title":"J\u00a0Mol Biol"},{"issue":"18","key":"10.1016\/j.hfc.2024.02.002_bib34","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1073\/pnas.1423174112","article-title":"pH-induced molecular shedding drives the formation of amyloid fibril-derived oligomers","volume":"112","author":"Tipping","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"48","key":"10.1016\/j.hfc.2024.02.002_bib35","doi-asserted-by":"crossref","first-page":"e202210675","DOI":"10.1002\/anie.202210675","article-title":"pH dependence of amyloid-beta fibril assembly kinetics: unravelling the microscopic molecular processes","volume":"61","author":"Tian","year":"2022","journal-title":"Angew Chem Int Ed Engl"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib36","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1073\/pnas.1317488111","article-title":"Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis","volume":"111","author":"Mangione","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.hfc.2024.02.002_bib37","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A\u00a0novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol Med"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010699","article-title":"The role of proteolysis in amyloidosis","volume":"24","author":"Acquasaliente","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.hfc.2024.02.002_bib39","doi-asserted-by":"crossref","first-page":"e0125392","DOI":"10.1371\/journal.pone.0125392","article-title":"Transthyretin amyloidosis: chaperone concentration changes and increased proteolysis in the pathway to disease","volume":"10","author":"da Costa","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCHEARTFAILURE.108.788687","article-title":"Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition","volume":"1","author":"Biolo","year":"2008","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2024.02.002_bib41","doi-asserted-by":"crossref","first-page":"e005868","DOI":"10.1161\/JAHA.112.005868","article-title":"Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis","volume":"2","author":"Tanaka","year":"2013","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib42","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/path.1553","article-title":"Cleavage of AL amyloid proteins and AL amyloid deposits by cathepsins B, K, and L","volume":"203","author":"Bohne","year":"2004","journal-title":"J\u00a0Pathol"},{"issue":"6","key":"10.1016\/j.hfc.2024.02.002_bib43","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1007\/s10741-022-10237-7","article-title":"Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis","volume":"27","author":"Morfino","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10.1016\/j.hfc.2024.02.002_bib44","first-page":"035102","article-title":"Simulations of nucleation and elongation of amyloid fibrils","volume":"130","author":"Zhang","year":"2009","journal-title":"J\u00a0Chem Phys"},{"issue":"15","key":"10.1016\/j.hfc.2024.02.002_bib45","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1074\/jbc.RA118.005257","article-title":"A\u00a0pair of peptides inhibits seeding of the hormone transporter transthyretin into amyloid fibrils","volume":"294","author":"Saelices","year":"2019","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.hfc.2024.02.002_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pnmrs.2015.05.002","article-title":"Mechanisms of amyloid formation revealed by solution NMR","volume":"88-89","author":"Karamanos","year":"2015","journal-title":"Prog Nucl Magn Reson Spectrosc"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41598-018-37230-1","article-title":"Transthyretin aggregation pathway toward the formation of distinct cytotoxic oligomers","volume":"9","author":"Dasari","year":"2019","journal-title":"Sci Rep"},{"issue":"2\u20133","key":"10.1016\/j.hfc.2024.02.002_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/jsbi.2000.4289","article-title":"Review: modulating factors in amyloid-beta fibril formation","volume":"130","author":"McLaurin","year":"2000","journal-title":"J\u00a0Struct Biol"},{"issue":"10","key":"10.1016\/j.hfc.2024.02.002_bib49","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1073\/pnas.92.10.4299","article-title":"Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis","volume":"92","author":"Tennent","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.hfc.2024.02.002_bib50","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40120-020-00217-0","article-title":"A\u00a0narrative review of the role of transthyretin in health and disease","volume":"9","author":"Liz","year":"2020","journal-title":"Neurol Ther"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1515\/bmc-2013-0038","article-title":"Transthyretin: a multifaceted protein","volume":"5","author":"Vieira","year":"2014","journal-title":"Biomol Concepts"},{"issue":"11","key":"10.1016\/j.hfc.2024.02.002_bib52","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1021\/bi301313b","article-title":"Age-related oxidative modifications of transthyretin modulate its amyloidogenicity","volume":"52","author":"Zhao","year":"2013","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib53","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.hfc.2024.02.002_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116336","article-title":"Molecular mechanism of pathogenesis and treatment strategies for AL Amyloidosis","volume":"23","author":"Ikura","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10.1016\/j.hfc.2024.02.002_bib55","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2010-02-268987","article-title":"Hyperdiploidy is less frequent in AL amyloidosis compared with monoclonal gammopathy of undetermined significance and inversely associated with translocation t(11;14)","volume":"117","author":"Bochtler","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.hfc.2024.02.002_bib56","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1016\/j.jmb.2016.08.021","article-title":"The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains","volume":"428","author":"Morgan","year":"2016","journal-title":"J\u00a0Mol Biol"},{"issue":"3","key":"10.1016\/j.hfc.2024.02.002_bib57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2016-10-743997","article-title":"Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry","volume":"129","author":"Kourelis","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hfc.2024.02.002_bib58","doi-asserted-by":"crossref","first-page":"e006075","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circulation Heart failure"},{"issue":"9 Pt 1","key":"10.1016\/j.hfc.2024.02.002_bib59","doi-asserted-by":"crossref","first-page":"746","DOI":"10.7326\/0003-4819-134-9_Part_1-200105010-00011","article-title":"Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease","volume":"134","author":"Dember","year":"2001","journal-title":"Annals of internal medicine"},{"issue":"16","key":"10.1016\/j.hfc.2024.02.002_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26165091","article-title":"Significance of oligomeric and fibrillar species in amyloidosis: insights into pathophysiology and treatment","volume":"26","author":"Koike","year":"2021","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.hfc.2024.02.002_bib61","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","article-title":"Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins","volume":"95","author":"Lambert","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1016\/j.hfc.2024.02.002_bib62","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","article-title":"Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways","volume":"21","author":"Sousa","year":"2001","journal-title":"J\u00a0Neurosci"},{"issue":"8","key":"10.1016\/j.hfc.2024.02.002_bib63","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.hfc.2024.02.002_bib64","doi-asserted-by":"crossref","first-page":"688","DOI":"10.15252\/emmm.201505318","article-title":"Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity","volume":"7","author":"Guan","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.hfc.2024.02.002_bib65","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1038\/srep01278","article-title":"Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes","volume":"3","author":"Levinson","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.hfc.2024.02.002_bib66","article-title":"Serum and tissue light-chains as disease biomarkers and targets for treatment in AL amyloidosis","volume":"6","author":"Camerini","year":"2022","journal-title":"Vessel Plus"},{"issue":"6","key":"10.1016\/j.hfc.2024.02.002_bib67","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.2353\/ajpath.2006.060183","article-title":"Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts","volume":"169","author":"Monis","year":"2006","journal-title":"Am J Pathol"},{"issue":"12","key":"10.1016\/j.hfc.2024.02.002_bib68","doi-asserted-by":"crossref","first-page":"5642","DOI":"10.1021\/pr400583h","article-title":"Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses","volume":"12","author":"Brambilla","year":"2013","journal-title":"J\u00a0Proteome Res"},{"issue":"9","key":"10.1016\/j.hfc.2024.02.002_bib69","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1073\/pnas.0912263107","article-title":"Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway","volume":"107","author":"Shi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib70","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140155","article-title":"Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage","volume":"35","author":"Manral","year":"2015","journal-title":"Biosci Rep"},{"issue":"9","key":"10.1016\/j.hfc.2024.02.002_bib71","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1073\/pnas.0400062101","article-title":"Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture","volume":"101","author":"Reixach","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib72","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2011.04.133","article-title":"Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs","volume":"410","author":"Bourgault","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"41","key":"10.1016\/j.hfc.2024.02.002_bib73","doi-asserted-by":"crossref","first-page":"16291","DOI":"10.1073\/pnas.1315112110","article-title":"Amyloid and inflammation","volume":"110","author":"Gorevic","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib74","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/ejhf.1039","article-title":"Intramyocardial inflammation predicts adverse outcome in patients with cardiac AL amyloidosis","volume":"20","author":"Siegismund","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10.1016\/j.hfc.2024.02.002_bib75","doi-asserted-by":"crossref","first-page":"e020358","DOI":"10.1161\/JAHA.120.020358","article-title":"Amyloid deposits and fibrosis on left ventricular endomyocardial biopsy correlate with extracellular volume in cardiac amyloidosis","volume":"10","author":"Pucci","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.hfc.2024.02.002_bib76","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/labinvest.2013.83","article-title":"Fibroblasts endocytose and degrade transthyretin aggregates in transthyretin-related amyloidosis","volume":"93","author":"Misumi","year":"2013","journal-title":"Lab Invest"},{"key":"10.1016\/j.hfc.2024.02.002_bib77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12968-016-0240-7","article-title":"Regional myocardial microvascular dysfunction in cardiac amyloid light-chain amyloidosis: assessment with 3T cardiovascular magnetic resonance","volume":"18","author":"Li","year":"2016","journal-title":"J\u00a0Cardiovasc Magn Reson"},{"issue":"3","key":"10.1016\/j.hfc.2024.02.002_bib78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/13506129.2022.2155133","article-title":"Collagen inhibits phagocytosis of amyloid in\u00a0vitro and in\u00a0vivo and may act as a 'don't eat me' signal","volume":"30","author":"Jackson","year":"2023","journal-title":"Amyloid"},{"issue":"2","key":"10.1016\/j.hfc.2024.02.002_bib79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"issue":"18","key":"10.1016\/j.hfc.2024.02.002_bib80","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/cvr\/cvac119","article-title":"Transthyretin cardiac amyloidosis","volume":"118","author":"Porcari","year":"2023","journal-title":"Cardiovasc Res"},{"issue":"6","key":"10.1016\/j.hfc.2024.02.002_bib81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/76216","article-title":"Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis","volume":"6","author":"Yan","year":"2000","journal-title":"Nature medicine"},{"issue":"3","key":"10.1016\/j.hfc.2024.02.002_bib82","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/PL00000706","article-title":"Immunoglobulin light chains, glycosaminoglycans, and amyloid","volume":"57","author":"Stevens","year":"2000","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"10.1016\/j.hfc.2024.02.002_bib83","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.hfc.2024.02.002_bib84","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clin Med (Lond)"},{"issue":"45","key":"10.1016\/j.hfc.2024.02.002_bib85","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.hfc.2024.02.002_bib86","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/ejhf.2650","article-title":"Atrial amyloidosis: mechanisms and clinical manifestations","volume":"24","author":"Vergaro","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib87","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4103\/jcecho.jcecho_22_17","article-title":"Left ventricle relative apical sparing in cardiac amyloidosis","volume":"27","author":"Nardozza","year":"2017","journal-title":"J\u00a0Cardiovasc Echogr"},{"issue":"9","key":"10.1016\/j.hfc.2024.02.002_bib88","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/ehjci\/jead107","article-title":"Relative apical sparing in cardiac amyloidosis is not always explained by an amyloid gradient","volume":"24","author":"De Gaspari","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib89","doi-asserted-by":"crossref","first-page":"e12967","DOI":"10.1111\/anec.12967","article-title":"Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis","volume":"27","author":"Ng","year":"2022","journal-title":"Ann Noninvasive Electrocardiol"},{"issue":"2","key":"10.1016\/j.hfc.2024.02.002_bib90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure-volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: transthyretin cardiac amyloid study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.hfc.2024.02.002_bib91","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib92","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10741-023-10350-1","article-title":"Valvular heart disease in patients with cardiac amyloidosis","volume":"29","author":"Aimo","year":"2023","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10.1016\/j.hfc.2024.02.002_bib94","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/his.12793","article-title":"Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases","volume":"68","author":"Larsen","year":"2016","journal-title":"Histopathology"},{"issue":"12","key":"10.1016\/j.hfc.2024.02.002_bib95","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis","volume":"165","author":"Ng","year":"2005","journal-title":"Arch Intern Med"},{"issue":"18","key":"10.1016\/j.hfc.2024.02.002_bib96","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1161\/CIRCULATIONAHA.113.006242","article-title":"Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis","volume":"129","author":"Quarta","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.hfc.2024.02.002_bib97","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"10.1016\/j.hfc.2024.02.002_bib98","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"Amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.hfc.2024.02.002_bib99","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"Suppl B","key":"10.1016\/j.hfc.2024.02.002_bib100","doi-asserted-by":"crossref","first-page":"B79","DOI":"10.1093\/eurheartjsupp\/suad079","article-title":"Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis","volume":"25","author":"Emdin","year":"2023","journal-title":"Eur Heart J Suppl"}],"container-title":["Heart Failure Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551713624000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:26:33Z","timestamp":1717590393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551713624000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1551713624000163"],"URL":"https:\/\/doi.org\/10.1016\/j.hfc.2024.02.002","relation":{},"ISSN":["1551-7136"],"issn-type":[{"value":"1551-7136","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology of Cardiac Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Heart Failure Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hfc.2024.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}